HASBROUCK HEIGHTS, N.J., Dec. 19, 2008 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that recent successful clinical trial results for NX-1207, the Company's new drug for benign prostatic hyperplasia (BPH), is featured in the Urology Times, the widely distributed and most read publication of U.S. urologists. The Urology Times article entitled "Investigational benign prostatic hyperplasia drug improves urgency, frequency" refers to the 47% reduction in symptoms of urgency and 43% improvement in the frequency of urination, both of which were largely maintained for one year after a single treatment with NX-1207.
